Decreased expression of protein tyrosine phosphatase non‑receptor type 12 is involved in the proliferation and recurrence of bladder transitional cell carcinoma

Piao,Yongrui; Liu,Xiankui; Lin,Zhenhua; Jin,Zhehu; Jin,Xuanshun; Yuan,Kuichang; Wu,Wenyuan

doi:10.3892/ol.2015.3454

Decreased expression of protein tyrosine phosphatase non‑receptor type 12 is involved in the proliferation and recurrence of bladder transitional cell carcinoma

Authors:
- Yongrui Piao
- Xiankui Liu
- Zhenhua Lin
- Zhehu Jin
- Xuanshun Jin
- Kuichang Yuan
- Wenyuan Wu
View Affiliations

Affiliations: Department of Urology, Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, P.R. China, Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Pathology, Yanbian University Medical College, Yanji, Jilin 133000, P.R. China, Department of Dermatology and Venereology, Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, P.R. China, Department of Cardiology, Affiliated Hospital of Yanbian University, Yanji, Jilin 133000, P.R. China
Published online on: July 3, 2015 https://doi.org/10.3892/ol.2015.3454
Pages: 1620-1626

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein tyrosine phosphatase non‑receptor type 12 (PTPN12) has been shown to be involved in the development of a number of types of carcinoma. However, the effect of PTPN12 on the proliferation and recurrence of human bladder transitional cell carcinoma (TCC) is unclear. The present study aimed to investigate the expression and function of PTPN12 in human TCC. Samples from 164 patients with TCC, in addition to 146 patients undergoing bladder surgery for indications other than TCC, were examined. PTPN12 protein expression was examined using immunohistochemistry and western blotting, and PTPN12 mRNA expression was examined using reverse transcription‑quantitative polymerase chain reaction. PTPN12 expression was increased following transfection with the PTPN12‑expressing, pcDEF3 vector, and PTPN12 expression was decreased by RNA interference, in four TCC cell lines. The proliferation of TCC cells was analyzed by a WST‑1 assay and in xenografts on BALB/C nude mice. The effect of PTPN12 on tumor recurrence was analyzed by adhesion, migration and invasion assays in TCC cell lines. PTPN12 expression was significantly decreased in TCC tissues compared with that in normal urothelium, and the level of PTPN12 expression was negatively correlated with tumor size, pathological grade, clinical stage and tumor recurrence. Furthermore, decreased expression of PTPN12 significantly enhanced the proliferation of TCC cells in vitro and in vivo. TCC cells with lower levels of PTPN12 exhibited greater adhesion, migration and invasion. In conclusion, PTPN12 expression is downregulated in human TCC. Restoring PTPN12 activity may represent a novel therapeutic strategy for this disease.

View Figures

View References

1	Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol. 279:289–293. 2009. View Article : Google Scholar
2	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
3	Jacobs BL, Lee CT and Montie JE: Bladder cancer in 2010: How far have we come? CA Cancer J Clin. 60:244–272. 2010. View Article : Google Scholar : PubMed/NCBI
4	Shariat SF, Karakiewicz PI, Palapattu GS, et al: Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: A contemporary series from the Bladder Cancer Research Consortium. J Urol. 176:2414–2422. 2006. View Article : Google Scholar : PubMed/NCBI
5	Morgan TM and Clark PE: Bladder cancer. Curr Opin Oncol. 22:242–249. 2010. View Article : Google Scholar : PubMed/NCBI
6	Kumar V, Abbas AK and Fausto N: 8th Philadelephia: Elsevier. Pathologic Basis of Disease. 976–980. 2010.
7	Hsu JL, Huang SY, Chow NH and Chen SH: Stable-isotope dimethyl labeling for quantitative proteomics. Anal Chem. 75:6843–6852. 2003. View Article : Google Scholar : PubMed/NCBI
8	Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2:127–137. 2001. View Article : Google Scholar : PubMed/NCBI
9	Hunter T: Tyrosine phosphorylation: Thirty years and counting. Curr Opin Cell Biol. 21:140–146. 2009. View Article : Google Scholar : PubMed/NCBI
10	Villa-Moruzzi E: Tyrosine phosphatases in the HER2-directed motility of ovarian cancer cells: Involvement of PTPN12, ERK5 and FAK. Anal Cell Pathol (Amst). 34:101–112. 2011. View Article : Google Scholar : PubMed/NCBI
11	Xunyi Y, Zhentao Y, Dandan J and Funian L: Clinicopathological significance of PTPN12 expression in human breast cancer. Braz J Med Biol Res. 45:1334–1340. 2012. View Article : Google Scholar : PubMed/NCBI
12	Sun T, Aceto N, Meerbrey KL, et al: Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 144:703–718. 2011. View Article : Google Scholar : PubMed/NCBI
13	Cao X, Li Y, Luo RZ, He LR, et al: Tyrosine-protein phosphatase nonreceptor type 12 is a novel prognostic biomarker for esophageal squamous cell carcinoma. Ann Thorac Surg. 93:1674–1680. 2012. View Article : Google Scholar : PubMed/NCBI
14	Espejo R, Rengifo-Cam W, Schaller MD, Evers BM and Sastry SK: PTPPEST controls motility, adherens junction assembly and Rho GTPase activity in colon cancer cells. Am J Physiol Cell Physiol. 299:C454–C463. 2010. View Article : Google Scholar : PubMed/NCBI
15	Zheng Y, Yang W, Xia Y, et al: Ras-induced and extracellular signal-regulated kinase 1 and 2 phosphorylation-dependent isomerization of protein tyrosine phosphatase (PTP)-PEST by PIN1 promotes FAK dephosphorylation by PTP-PEST. Mol Cell Biol. 31:4258–4269. 2011. View Article : Google Scholar : PubMed/NCBI
16	Davidson D, Shi X, Zhong MC, Rhee I and Veillette A: The phosphatase PTP-PEST promotes secondary T cell responses by dephosphorylating the protein tyrosine kinase Pyk2. Immunity. 33:167–180. 2010. View Article : Google Scholar : PubMed/NCBI
17	Streit S, Ruhe JE, Knyazev P, et al: PTP-PEST phosphatase variations in human cancer. Cancer Genet Cytogenet. 170:48–53. 2006. View Article : Google Scholar : PubMed/NCBI
18	Kapur U, Antic T, Venkataraman G, Durazo-Arvizu R, Quek MM, Flanigan RC and Wojcik EM: Validation of World Health Organization/International Society of Urologic Pathology 2004 classification schema for bladder urothelial carcinomas using quantitative nuclear morphometry: Identification of predictive features using bootstrap method. Urology. 70:1028–1033. 2007. View Article : Google Scholar : PubMed/NCBI
19	Streit S, Ruhe JE, Knyazev P, et al: PTP-PEST phosphatase variations in human cancer. Cancer Genet Cytogenet. 170:48–53. 2006. View Article : Google Scholar : PubMed/NCBI
20	Lerner SP: Bladder cancer clinical trials. Urol Oncol. 23:275–279. 2005. View Article : Google Scholar : PubMed/NCBI
21	Mitsumori K, Tsuchiya N, Habuchi T, et al: Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection. BJU Int. 94:317–321. 2004. View Article : Google Scholar : PubMed/NCBI
22	Sylvester RJ, Oosterlinck W and van der Meijden AP: A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol. 171:2186–2190. 2004. View Article : Google Scholar : PubMed/NCBI
23	Brausi M, Collette L and Kurth K: Variability in the recurrence rate at first follow up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies. Eur Urol. 41:523–531. 2002. View Article : Google Scholar : PubMed/NCBI
24	Luo RZ, Cai PQ, Li M, et al: Decreased expression of PTPN12 correlates with tumor recurrence and poor survival of patients with hepatocellular carcinoma. PLoS One. 9:e855922014. View Article : Google Scholar : PubMed/NCBI
25	Ajili F, Darouiche A, Chebil M and Boubaker S: The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy. Ultrastruct Pathol. 37:249–253. 2013. View Article : Google Scholar : PubMed/NCBI
26	Mares J, Szakacsova M, Soukup V, Duskova J, Horinek A and Babjuk M: Prediction of recurrence in low and intermediate risk non-muscle invasive bladder cancer by real-time quantitative PCR analysis: cDNA microarray results. Neoplasma. 60:295–301. 2013. View Article : Google Scholar : PubMed/NCBI
27	Xu T, Zhu Z, Zhang X, Wang X, Zhong S, Zhang M and Shen Z: Predicting recurrence and progression in chinese patients with nonmuscle-invasive bladder cancer using EORTC and CUETO scoring models. Urology. 82:387–393. 2013. View Article : Google Scholar : PubMed/NCBI
28	Hafner C, Knuechel R, Zanardo L, et al: Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract. Oncogene. 20:4910–4015. 2001. View Article : Google Scholar : PubMed/NCBI
29	Shang D, Liu Y, Yang P, Chen Y and Tian Y: TGFBI-promoted adhesion, migration and invasion of human renal cell carcinoma depends on inactivation of von Hippel-Lindau tumor suppressor. Urology. 79:e1–e7. 2012. View Article : Google Scholar : PubMed/NCBI